Compare BFAM & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFAM | GH |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.9B |
| IPO Year | 1997 | 2018 |
| Metric | BFAM | GH |
|---|---|---|
| Price | $104.40 | $103.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $131.17 | $79.19 |
| AVG Volume (30 Days) | 699.2K | ★ 2.9M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.95 | N/A |
| EPS | ★ 3.47 | N/A |
| Revenue | ★ $2,874,055,000.00 | $902,569,000.00 |
| Revenue This Year | $11.17 | $34.72 |
| Revenue Next Year | $6.93 | $26.46 |
| P/E Ratio | $30.27 | ★ N/A |
| Revenue Growth | 9.38 | ★ 30.38 |
| 52 Week Low | $91.49 | $29.91 |
| 52 Week High | $132.99 | $112.43 |
| Indicator | BFAM | GH |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 66.40 |
| Support Level | $101.07 | $98.23 |
| Resistance Level | $101.65 | $112.43 |
| Average True Range (ATR) | 2.66 | 5.44 |
| MACD | 0.76 | -0.54 |
| Stochastic Oscillator | 93.10 | 64.46 |
Bright Horizons Family Solutions Inc provider of early education and child care, family care solutions, and workforce education services that help working families and client employees personally and professionally. It provides services under multi-year contracts with employers that offer early education and child care, back-up care, and educational advisory services as part of their employee benefits package. The company has three business segments; full-service center-based child care, backup care, and educational advisory services. The majority of the revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, and Others.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.